Marshall Edwards, Inc.(Nasdaq:MSHL) announced the publication of results from a pre-clinical study of its investigational compound NV-128, that’s showing activity in chemotherapy-resistant ovarian cancer stem cells. MSH stock gained over 130% on 150X 10day average volume as of 10 a.m. on July 27th. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian […]